Citigroup
RARE icon

Citigroup’s Ultragenyx Pharmaceutical RARE Stock Holding History

Citigroup’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.61M Buy
315,440
+245,929
+354% +$5.54M ﹤0.01% 1753
2025
Q4 		$1.6M Buy
69,511
+43,322
+165% +$1.42M ﹤0.01% 2809
2025
Q3 		$788K Sell
26,189
-5,631
-18% -$169K ﹤0.01% 3314
2025
Q2 		$1.16M Sell
31,820
-81,308
-72% -$2.93M ﹤0.01% 3083
2025
Q1 		$4.1M Buy
113,128
+46,207
+69% +$1.92M ﹤0.01% 2082
2024
Q4 		$2.82M Buy
66,921
+23,428
+54% +$1.16M ﹤0.01% 2512
2024
Q3 		$2.42M Buy
43,493
+23,018
+112% +$1.17M ﹤0.01% 2496
2024
Q2 		$842K Sell
20,475
-136,374
-87% -$5.82M ﹤0.01% 3030
2024
Q1 		$7.32M Buy
156,849
+46,339
+42% +$2.19M ﹤0.01% 1462
2023
Q4 		$5.28M Buy
110,510
+19,930
+22% +$773K ﹤0.01% 1552
2023
Q3 		$3.23M Buy
90,580
+19,113
+27% +$757K ﹤0.01% 1672
2023
Q2 		$3.3M Sell
71,467
-84,568
-54% -$3.92M ﹤0.01% 1785
2023
Q1 		$6.26M Buy
156,035
+62,510
+67% +$2.68M ﹤0.01% 1372
2022
Q4 		$4.33M Sell
93,525
-39,859
-30% -$1.57M ﹤0.01% 1536
2022
Q3 		$5.52M Buy
133,384
+48,918
+58% +$2.51M ﹤0.01% 1499
2022
Q2 		$5.04M Buy
84,466
+61,083
+261% +$3.76M ﹤0.01% 1541
2022
Q1 		$1.7M Sell
23,383
-35,565
-60% -$2.47M ﹤0.01% 2505
2021
Q4 		$4.96M Buy
58,948
+29,199
+98% +$2.38M ﹤0.01% 1834
2021
Q3 		$2.68M Sell
29,749
-25,416
-46% -$2.3M ﹤0.01% 2304
2021
Q2 		$5.26M Buy
55,165
+7,137
+15% +$744K ﹤0.01% 1851
2021
Q1 		$5.47M Buy
48,028
+6,061
+14% +$825K ﹤0.01% 1723
2020
Q4 		$5.81M Buy
41,967
+35,927
+595% +$4.26M ﹤0.01% 1959
2020
Q3 		$496K Sell
6,040
-31,334
-84% -$2.6M ﹤0.01% 3851
2020
Q2 		$2.92M Sell
37,374
-11,768
-24% -$779K ﹤0.01% 2375
2020
Q1 		$2.18M Buy
49,142
+28,701
+140% +$1.49M ﹤0.01% 2392
2019
Q4 		$873K Sell
20,441
-40,759
-67% -$1.68M ﹤0.01% 3905
2019
Q3 		$2.62M Buy
61,200
+28,565
+88% +$1.55M ﹤0.01% 2568
2019
Q2 		$2.07M Buy
32,635
+7,758
+31% +$494K ﹤0.01% 2804
2019
Q1 		$1.73M Sell
24,877
-101,404
-80% -$5.79M ﹤0.01% 2814
2018
Q4 		$5.49M Buy
126,281
+8,370
+7% +$457K 0.01% 1737
2018
Q3 		$9M Buy
117,911
+106,049
+894% +$8.63M 0.01% 1358
2018
Q2 		$911K Sell
11,862
-24,017
-67% -$1.55M ﹤0.01% 3455
2018
Q1 		$1.83M Sell
35,879
-5,240
-13% -$264K ﹤0.01% 2675
2017
Q4 		$1.91M Buy
41,119
+16,703
+68% +$819K ﹤0.01% 2721
2017
Q3 		$1.3M Sell
24,416
-7,758
-24% -$460K ﹤0.01% 3102
2017
Q2 		$2M Buy
32,174
+13,278
+70% +$800K ﹤0.01% 2600
2017
Q1 		$1.28M Sell
18,896
-110,048
-85% -$8.39M ﹤0.01% 2958
2016
Q4 		$9.07M Buy
128,944
+116,454
+932% +$8.26M 0.01% 1272
2016
Q3 		$886K Buy
12,490
+3,555
+40% +$227K ﹤0.01% 3347
2016
Q2 		$437K Sell
8,935
-27,950
-76% -$1.81M ﹤0.01% 3811
2016
Q1 		$2.33M Buy
36,885
+24,554
+199% +$1.61M ﹤0.01% 2320
2015
Q4 		$1.38M Buy
12,331
+10,163
+469% +$1.02M ﹤0.01% 2794
2015
Q3 		$209K Sell
2,168
-780
-26% -$89.3K ﹤0.01% 4453
2015
Q2 		$301K Sell
2,948
-5,203
-64% -$404K ﹤0.01% 4129
2015
Q1 		$506K Sell
8,151
-1,025
-11% -$56.9K ﹤0.01% 3734
2014
Q4 		$403K Buy
9,176
+8,306
+955% +$381K ﹤0.01% 4088
2014
Q3 		$49K Buy
870
+545
+168% +$27.4K ﹤0.01% 5321
2014
Q2 		$14K Buy
325
+301
+1,254% +$12.4K ﹤0.01% 6016
2014
Q1 		$1K Buy
+24
New +$1.24K ﹤0.01% 6884

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citigroup's RARE Position: Q1 2026 in Review

Citigroup increased its Ultragenyx Pharmaceutical (RARE) stake by 354% in Q1 2026, buying an estimated $5.54M and bringing the position to 315,440 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Citigroup first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $9.07M in Q4 2016. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Citigroup held 315,440 shares of Ultragenyx Pharmaceutical worth $6.61M as of Q1 2026.
  • Citigroup bought 245,929 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.54M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1753 holding.
  • Citigroup first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Ultragenyx Pharmaceutical position peaked at $9.07M in Q4 2016.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.